Designing Longevity
Skip to main content
Strong EvidencePeptide

Tesamorelin

Egrifta

Growth Hormone-Releasing Hormone Analog

Last updated: August 2026
Share:

Evidence Level: Strong Evidence

Multiple large human trials, FDA approval, established safety profile

Regulatory Status: FDA-approved (Egrifta) since 2010 for reducing excess abdominal fat in people with HIV-associated lipodystrophy. Prescribed off-label for other uses.

Tesamorelin is a longer-lasting version of that prompts your pituitary to release growth hormone. It is FDA-approved under the brand name Egrifta for reducing deep abdominal fat in people with HIV. Among growth hormone peptides it is unusual: it has large randomized trials measuring things that matter, not just hormone levels.

How It Works

Tesamorelin is with a chemical modification (a trans-3-hexenoyl group) attached to the front end that protects it from the enzyme that would otherwise chew it up. The result is a GHRH analog that survives long enough in the bloodstream to be dosed once daily rather than several times a day.

What it targets. The approved use is , the deep fat that packs in around your organs rather than sitting under the skin. This distinction matters. Visceral fat is the metabolically dangerous kind, the type associated with insulin resistance, liver fat, and cardiovascular risk. Subcutaneous fat, the kind you can pinch, is far less harmful.

Growth hormone preferentially mobilizes , which is why a analog works here at all. In the pivotal trials, tesamorelin reduced visceral fat substantially while leaving subcutaneous fat largely alone. That is an unusual and clinically useful selectivity.

The cognition finding. In 2012, a separate randomized trial gave 1mg of tesamorelin nightly for 20 weeks to 152 older adults, some with mild cognitive impairment and some cognitively healthy. It improved executive function, and to a smaller degree short-term verbal memory, in both groups. This is the single most interesting piece of evidence in the entire growth hormone peptide category, because it is a real randomized controlled trial measuring a real outcome rather than a hormone level.

It is also, importantly, one trial. It has not been replicated at scale, the were modest, and 20 weeks tells you nothing about whether the benefit persists or whether it changes anyone's trajectory toward dementia.

Why it is not a general anti-aging drug. Everything approved here was studied in a specific population: people with HIV who developed abnormal accumulation on antiretroviral therapy. Whether the same effects appear in a healthy 50-year-old who simply wants less belly fat is an open question, not an established fact. It is prescribed off-label for exactly that anyway.

Evidence by Outcome

Each claim below is rated using a GRADE-aligned five-tier system. Same molecule, different outcomes, different evidence.

Evidence at a glance

How we grade

Want to see how this compares to every other peptide? Browse the full evidence matrix, where every graded claim is grouped by outcome and sorted by certainty.

Weight lossHigh certainty

Reduces visceral abdominal fat by roughly 15% over 26 weeks.

Population: Adults with HIV and excess abdominal fat accumulation associated with antiretroviral therapy

Why this rating

Direct evidence from a large, well-designed, placebo-controlled randomized trial published in the New England Journal of Medicine, with an imaging-based objective endpoint and a clinically meaningful effect. Replicated in a second 26-week trial and sufficient to support FDA approval. No serious GRADE downgrade factors apply for this population.

Supporting studies

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade
Cognitive functionLow certainty

Improves executive function in older adults, including those with mild cognitive impairment.

Population: Adults aged 55 to 87, both cognitively healthy and with mild cognitive impairment

Why this rating

This comes from a genuine randomized, double-blind, placebo-controlled trial, which is more than almost any other peptide marketed for cognition can claim. It is graded low rather than moderate because it is a single trial of 152 people over 20 weeks, the effect sizes were modest, it has not been independently replicated, and cognitive test scores are a surrogate for the outcome people actually care about, which is long-term cognitive trajectory.

GRADE downgrade factors applied

  • Imprecision: Wide confidence intervals or small sample size, the estimate could be substantially different.
  • Inconsistency: Heterogeneous results across studies that cannot be explained, or pending replication.
  • Indirectness: Studied population, intervention, comparator, or outcome differs from the question being answered.

Supporting studies

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade
Weight lossLow certainty

Reduces visceral fat in healthy adults without HIV.

Population: Healthy adults without HIV-associated lipodystrophy. This is the population most off-label prescriptions target.

Why this rating

The mechanism is not HIV-specific and the effect would be expected to carry over, but the pivotal trials enrolled people whose visceral fat accumulation was driven by antiretroviral therapy, which is a different underlying cause from ordinary age-related or diet-related visceral adiposity. Extrapolating across that gap is reasonable but unproven.

GRADE downgrade factors applied

  • Indirectness: Studied population, intervention, comparator, or outcome differs from the question being answered.

Supporting studies

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade

Potential Benefits

  • FDA-approved, which means an actual manufacturing standard, a known dose, and a real label
  • Reduced by about 15% versus a 5% increase on placebo in a 412-person randomized trial
  • Selectively targets deep while largely sparing subcutaneous fat
  • Improved lipid profiles alongside the fat reduction
  • Improved executive function in a separate 152-person randomized trial in older adults
  • Preserves natural pulsatile growth hormone release rather than overriding it
  • Also studied for liver fat in HIV-associated fatty liver disease, with positive results

Risks & Considerations

  • Approved only for HIV-associated . Every other use is off-label and less well supported
  • Expensive. As a branded specialty drug, cost is a major practical barrier
  • Requires daily subcutaneous injection
  • Can reduce insulin sensitivity and raise blood sugar, which needs monitoring
  • Joint pain, swelling, muscle aches, and injection site reactions are common
  • returns after discontinuation. It is not a one-time fix
  • Raises , which carries the same theoretical long-term growth-signal concerns as the rest of this class
  • The cognition result comes from a single unreplicated trial and should not be oversold

Dosing Information

Tesamorelin has an approved, labeled dose, which puts it in a different category from most peptides discussed on this site.

  • •Approved dose: 2mg subcutaneously once daily
  • •The cognition trial used 1mg nightly for 20 weeks
  • •Injected into the abdomen, rotating sites to avoid lipoatrophy
  • •Supplied as a powder requiring before use
  • •Nightly dosing aligns with the natural growth hormone pulse during early deep sleep
  • •Blood glucose and should be monitored during treatment

Need to mix this from a vial?

Use our reconstitution calculator to get the exact insulin syringe units to draw.

Practical Tips

  • 1If you want a growth hormone peptide and can get this one, it is the one with the best evidence behind it by a wide margin
  • 2Have fasting glucose and HbA1c checked before starting and periodically after. The insulin sensitivity effect is real
  • 3Do not expect subcutaneous fat loss. This drug targets the deep visceral compartment specifically
  • 4 comes back when you stop, so think about whether this is a bridge to something sustainable
  • 5Ask about cost and coverage before you get attached to the idea. Branded Egrifta is expensive
  • 6If a clinic offers tesamorelin, ask why, since an approved product exists

Key Research

Metabolic effects of a growth hormone-releasing factor in patients with HIV

New England Journal of Medicine, 2007

Over 26 weeks, tesamorelin reduced visceral adipose tissue by 15.2% while placebo increased it by 5.0%. Triglycerides and the cholesterol ratio also improved. Subcutaneous fat was not meaningfully affected.

View Study

Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial

Archives of Neurology, 2012

1mg of tesamorelin nightly for 20 weeks improved executive function, and to a lesser degree short-term verbal memory, in both cognitively healthy older adults and those with mild cognitive impairment.

View Study

Want to learn more?

Explore related content and talk to a healthcare provider.

Browse All TreatmentsFind Your Goal

Always consult a healthcare provider before starting any treatment.

Frequently Asked Questions

Is tesamorelin FDA-approved?

Yes. Tesamorelin has been FDA-approved since 2010 under the brand name Egrifta, for reducing excess abdominal fat in people with HIV-associated . That makes it one of very few peptides in the anti-aging and body composition conversation with a real approval, a labeled dose, and manufacturing oversight.

Does tesamorelin reduce belly fat?

It reduces , the deep fat around your organs, by about 15% over 26 weeks in the population it was studied in. It does not meaningfully reduce subcutaneous fat, the layer you can pinch. So your waist measurement may drop without much visible change in how your stomach looks. Visceral fat is the more metabolically harmful kind, so this is arguably the more valuable target.

Does tesamorelin improve memory?

A randomized controlled trial of 152 older adults found that 1mg nightly for 20 weeks improved executive function, and to a lesser degree short-term verbal memory, in both healthy participants and those with mild cognitive impairment. That is genuinely notable evidence. It is also a single unreplicated trial with modest over 20 weeks, so it is a promising signal rather than an established treatment.

Can I take tesamorelin if I do not have HIV?

Doctors do prescribe it off-label, and the mechanism is not HIV-specific. But you should understand what you are buying: the pivotal trials enrolled people whose accumulation was caused by antiretroviral therapy, which is a different underlying process from ordinary age-related belly fat. The extrapolation is reasonable and unproven, and cost is usually the bigger obstacle anyway.

What are the side effects of tesamorelin?

The most common are injection site reactions, joint pain, muscle aches, and swelling in the extremities. The one that needs actual monitoring is reduced insulin sensitivity: tesamorelin can raise blood sugar, so fasting glucose and HbA1c should be checked before starting and periodically during treatment. These are the classic effects of raising growth hormone.

How does tesamorelin compare to sermorelin or CJC-1295?

All three are analogs doing the same basic job. The difference is evidence. Tesamorelin has large randomized trials with imaging endpoints and an FDA approval. Sermorelin has an approval history for a pediatric indication but no adult outcome trials. CJC-1295 has a single published human pharmacology study measuring hormone levels. If evidence quality is your deciding factor, this is not a close call.

Does the fat come back if you stop tesamorelin?

Yes. Studies that followed people after discontinuation showed returning. Tesamorelin works while you take it by keeping growth hormone signaling elevated; it does not permanently change how your body stores fat. That makes it a maintenance therapy rather than a course of treatment.

New to Peptides?

Learn the basics of peptide therapy, how to inject safely, and what to look for in quality sources.

What Are Peptides? Peptide Safety Guide

Related Goals

The Weight Loss GuideThe Sharper Mind GuideThe Hormone Balance Guide

Compare Tesamorelin

Sermorelin vs Tesamorelin

Same mechanism, very different evidence

Related Peptides

SermorelinGrowth Hormone-Releasing Hormone Analog
CJC-1295 / IpamorelinGHRH Analog + Growth Hormone Secretagogue
SemaglutideGLP-1 Receptor Agonist

Disclaimer: This information is for educational purposes only and is not medical advice. Many peptides discussed are not FDA-approved for human use. Always consult with a qualified healthcare provider before starting any treatment. Evidence levels and regulatory status can change, this content was last updated August 2026.

Found this helpful? Share it or save it for later.

Share: